— Know what they know.
Not Investment Advice

News & Sentiment

Sentiment -46.0 1950 articles 1236 bullish 418 bearish Full Index →
Restaurant Brands International Inc. Announces Renewal of Normal Course Issuer B

Restaurant Brands International Inc. Announces Renewal of Normal Course Issuer Bid

MIAMI, Sept. 11, 2026 /CNW/ -- Restaurant Brands International Inc. (TSX: QSR) (NYSE: QSR) ("RBI") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of RBI's intention to renew its normal course issuer bid (the "NCIB") for its common shares....
bullish QSR.TO PRNewswire 9h ago
📰

Biodexa Pharmaceuticals reports 1H results

📰

3 things to look out for on Monday

📰

3 things to look out for on Monday

📰

3 things to look out for on Monday

📰

MindWalk Q1 Earnings Preview

📰

Wall Street Marks 25 Years Since 9/11

Get a jump start on the US trading day with Vonnie Quinn and Michael Mckee on "Bloomberg Open Interest." Twenty-five years after September 11th,...
📰

Sanofi: Information concerning the total number of voting rights and shares - August 2026 - Yahoo Finance

Sanofi: Information concerning the total number of voting rights and shares - August 2026  Yahoo Finance
📰

CON vs. MEDP: Which Stock Is the Better Value Option?

CON vs. MEDP: Which Stock Is the Better Value Option?
📰

CON vs. MEDP: Which Stock Is the Better Value Option?

CON vs. MEDP: Which Stock Is the Better Value Option?
📰

LCUT or HLN: Which Is the Better Value Stock Right Now?

LCUT vs. HLN: Which Stock Is the Better Value Option?
📰

TFX vs. PEN: Which Stock Is the Better Value Option?

TFX vs. PEN: Which Stock Is the Better Value Option?
📰

TFX vs. PEN: Which Stock Is the Better Value Option?

TFX vs. PEN: Which Stock Is the Better Value Option?
📰

Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer...
📰

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer...
📰

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could...
📰

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could...
📰

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
📰

Should Value Investors Buy Healthcare Services Group (HCSG) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks....
Investors Heavily Search Abbott Laboratories (ABT): Here is

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the...
📰
📰

The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio

Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks.
📰

The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio

Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks.
Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) ver

Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX)

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) and MeiraGTx (NASDAQ:MGTX – Get Free Report) are both healthcare companies, but which...
📰

TransCode Therapeutics CFO retires

📰

Top Research Reports for Goldman Sachs, RTX & Abbott

Goldman Sachs, RTX and Abbott headline today's research, with growth drivers, risks and strategic moves shaping their outlooks.
📰

Top Research Reports for Goldman Sachs, RTX & Abbott

Goldman Sachs, RTX and Abbott headline today's research, with growth drivers, risks and strategic moves shaping their outlooks.
The top 15 party schools in the US, ranked

The top 15 party schools in the US, ranked

Social life can shape a student's college experiences. This year, Florida State University in Tallahassee was ranked the top party school.
📰

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
📰

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellnes

Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellness Growth?

CVS is benefiting from pharmacy growth, AI investments and a discounted valuation, but reimbursement pressure and regulatory scrutiny remain key...
Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellnes

Should You Buy, Hold or Sell CVS Stock Amid Consumer Wellness Growth?

CVS is benefiting from pharmacy growth, AI investments and a discounted valuation, but reimbursement pressure and regulatory scrutiny remain key...
« Prev 1 2 3 4 Next »

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms